Session Type: Poster Session (Monday)
Session Time: 9:00AM-11:00AM
Background/Purpose: Secukinumab represents a relatively new approach to treating patients with psoriatic arthritis (PsA) and has shown promising results in RCTs. However, there is a lack of real-life evidence on secukinumab effectiveness. Hence, the aim of this study was to determine the 6- and 12-month secukinumab retention rates as well as the crude and LUNDEX corrected proportions of patients in remission and low disease activity (LDA) at 6 and 12 months after treatment initiation based on observational registries in Europe. This was assessed overall as well as by prior biologic disease-modifying anti-rheumatic drug (bDMARD)/targeted synthetic (ts)DMARD use.
Methods: Data from PsA patients treated with secukinumab in routine care from 11 countries in the European Spondyloarthritis (EuroSpA) Research Collaboration Network were pooled. Time from treatment initiation to data cut was ≥ 12 months regardless of treatment duration and cover start date between May 2015 and April 2018. Crude and LUNDEX1 adjusted Disease Activity Score with 28 joints and CRP (DAS28CRP) and Disease Activity index for PSoriatic Arthritis with 28 joints (DAPSA28) 2 remission and LDA rates were calculated. Group comparisons between b/tsDMARD naïve, and 1 or 2 or more prior b/tsDMARD users were performed with ANOVA, Kruskal-Wallis or Chi-square test, or with Kaplan-Meier analyses with log rank test, as appropriate.
Results: A total of 1134 PsA patients were included, thereof 21 patients who started treatment in year 2015, 375 in 2016, 623 in 2017 and 115 in 2018. Overall 6/12-month secukinumab retention rate was 85%/74% and significantly higher in b/tsDMARD naïve compared with non-naïve patients after 12, but not 6 months (table, figure). Overall 6- and 12-month DAS28< 2.6/DAPSA28≤4 was achieved by 33%/12% and 55%/18% of the patients, respectively and 6- and 12-month DAS28/DAPSA28 LDA by 52%/34% and 73%/49%, respectively. B/tsDMARD naïve patients compared with patients treated with 1 or 2 or more previous b/tsDMARDs had shorter time since diagnosis, higher baseline disease activity, a higher proportion were men and a higher proportion achieved LUNDEX adjusted 6-month remission.
Conclusion: This study of >1100 patients in 11 European countries provided real-world data on the effectiveness of secukinumab in patients with PsA, adding evidence to existing RCTs. A majority of the patients were treated with 2 or more previous b/tsDMARDs, were female and had long disease duration. Overall retention rate was 85%/74% at 6/12 months, respectively, with significantly higher retention rates for b/tsDMARD naïve compared with patients treated with 1 or 2 or more previous b/tsDMARDs after 12, but not 6 months. Overall, a higher proportion of bionaïve than previous b/tsDMARD users achieved remission, regardless of remission criteria.
References: 1Kristensen et al. Arthritis Rheum 2006, 54(2):600-606. 2Michelsen et al. Ann Rheum Dis 2018;77:1736-1741.
To cite this abstract in AMA style:Michelsen B, DiGuiseppe D, Loft A, Pombo-Suarez M, Mann H, Rotar Z, Iannone F, Kvien T, Santos M, Eklund K, Gudbjornsson B, Codreanu C, Yılmaz S, Askling J, Sánchez-Piedra C, Pavelka K, Tomsic M, Conti F, Sexton J, Santos H, Trokovic N, Love T, IONESCU R, Pehlivan Y, Nissen M, Macfarlane G, van der Horst-Bruinsma I, Georgiadis S, Midtbøll Ørnbjerg L, Heegaard Brahe C, Lund Hetland M, Østergaard M. Secukinumab Effectiveness in 1134 Patients with Psoriatic Arthritis Treated in Routine Clinical Practice in 11 European Countries in the EuroSpA Research Collaboration Network [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/secukinumab-effectiveness-in-1134-patients-with-psoriatic-arthritis-treated-in-routine-clinical-practice-in-11-european-countries-in-the-eurospa-research-collaboration-network/. Accessed September 26, 2021.
« Back to 2019 ACR/ARP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/secukinumab-effectiveness-in-1134-patients-with-psoriatic-arthritis-treated-in-routine-clinical-practice-in-11-european-countries-in-the-eurospa-research-collaboration-network/